Brief: Hanall Biopharma, Daewoong Pharmaceutical And Nurron Pharmaceuticals Initiate First-In-Human Phase 1 Clinical Study Of Hl192
12/10/2023 12:24
Oct 12 (Reuters) - Hanall Biopharma Co Ltd 009420.KS :
* HANALL BIOPHARMA, DAEWOONG PHARMACEUTICAL AND NURRON
PHARMACEUTICALS INITIATE FIRST-IN-HUMAN PHASE 1 CLINICAL STUDY
OF HL192
* HANALL BIOPHARMA: COS ALSO ENTERED PARTNERSHIP WITH NURRON
PHARMACEUTICALS TO EXPLORE POTENTIAL OF HL192 IN ARRAY OF
NEURODEGENERATIVE DISEASES
Source text for Eikon: ID:nPn88D6lQa
Further company coverage: 009420.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hanall Biopharma
See all newsQ2 2026 Operating Profit Up 567.4% QoQ, 388.5% YoY To Won 5.60 Billion
Brief: Hanall Biopharma Co Icc Rules Licensing Deal With Harbour Biomed Continues To Be Effective
Brief: Hanall Biopharma Q1 Operating Profit 839 Million Won, Swings To Profit From Year Earlier
Immunovant falls as drug for thyroid eye disease fails late-stage trials
Immunovant falls as eye disease therapy fails in late-stage studies